ADDvise Q1 2024: Organic growth set to start improving in H2 2024e - Redeye

Redeye updates its estimates and valuation following ADDvise releasing its Q1 2024 report, which featured weaker Healthcare sales and margins than we had anticipated. Lab’s first-quarter figures roughly aligned with our expectations. We judge organic growth should start improving in H2 2024e. We nudge down our estimates and valuation, though our long-term view of the equity story remains unchanged.

Länk till analysen i sin helhet: https://www.redeye.se/research/996438/addvise-q1-2024-organic-growth-set-to-start-improving-in-h2-2024e?utm_source=finwire&utm_medium=RSS